-
Research ethics: Not applicable.
-
Informed consent: Not applicable.
-
Author contributions: The authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: The authors state no conflict of interest.
-
Research funding: None declared.
-
Data availability: Not applicable.
References
1. van Schrojenstein Lantman, M, Çubukçu, HC, Boursier, G, Panteghini, M, Bernabeu-Andreu, FA, Milinkovic, N, et al.. on behalf of the European Federation of Clinical Chemistry, Laboratory Medicine EFLM Working Group Accreditation, ISO/CEN Standards WG-A/ISO. An approach for determining allowable between reagent lot variation. Clin Chem Lab Med 2022;60:681–8. https://doi.org/10.1515/cclm-2022-0083.Search in Google Scholar PubMed
2. CLSI. User evaluation of between-reagent lot variation; approved guideline. CLSI document EP26-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.Search in Google Scholar
3. CLSI. User evaluation of acceptability of a reagent lot change. In: CLSI guideline EP26, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2022.Search in Google Scholar
4. Miller, WG, Erek, A, Cunningham, TD, Oladipo, O, Scott, MG, Johnson, RE. Commutability limitations influence quality control results with different reagent lots. Clin Chem 2011;57:76–83. https://doi.org/10.1373/clinchem.2010.148106.Search in Google Scholar PubMed
5. Kim, S, Chang, J, Kim, SK, Park, S, Huh, J, Jeong, TD. Sample size and rejection limits for detecting reagent lot variability: analysis of the applicability of the Clinical and Laboratory Standards Institute (CLSI) EP26-A protocol to real-world clinical chemistry data. Clin Chem Lab Med 2020;59:127–38. https://doi.org/10.1515/cclm-2020-0454.Search in Google Scholar PubMed
© 2023 Walter de Gruyter GmbH, Berlin/Boston
